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Respiratory diseases in Italy already now represent an emergency (they are the 3rd ranking cause of death in the
world, and the 2nd if Lung cancer is included). In countries similar to our own, they result as the principal cause for
a visit to the general practitioner (GP) and the second main cause after injury for recourse to Emergency Care. Their
frequency is probably higher than estimated (given that respiratory diseases are currently underdiagnosed). The
trend is towards a further increase due to epidemiologic and demographic factors (foremost amongst which are
the widespread diffusion of cigarette smoking, the increasing mean age of the general population, immigration,
and pollution). Within the more general problem of chronic disease care, chronic respiratory diseases (CRDs)
constitute one of the four national priorities in that they represent an important burden for society in terms of
mortality, invalidity, and direct healthcare costs. The strategy suggested by the World Health Organization (WHO) is
an integrated approach consisting of three goals: inform about health, reduce risk exposure, improve patient care.
The three goals are translated into practice in the three areas of prevention (1-primary, 2-secondary, 3-tertiary) as:
1) actions of primary (universal) prevention targeted at the general population with the aim to control the causes
of disease, and actions of Predictive Medicine - again addressing the general population but aimed at measuring the
individual’s risk for disease insurgence; 2) actions of early diagnosis targeted at groups or - more precisely - subgroups
identified as at risk; 3) continuous improvement and integration of care and rehabilitation support - destined at the
greatest possible number of patients, at all stages of disease severity. In Italy, COPD care is generally still inadequate.
Existing guidelines, institutional and non-institutional, are inadequately implemented: the international guidelines are
not always adaptable to the Italian context; the document of the Agency for Regional Healthcare Services (AGE.NA.S) is
a more suited compendium for consultation, and the recent joint statement on integrated COPD management of the
three major Italian scientific Associations in the respiratory area together with the contribution of a Society of General
Medicine deals prevalently with some critical issues (appropriateness of diagnosis, pharmacological treatment,
rehabilitation, continuing care); also the document “Care Continuity: Chronic Obstructive Pulmonary Disease (COPD)” of
the Global Alliance against chronic Respiratory Diseases (GARD)-Italy does not treat in depth the issue of early diagnosis.
The present document – produced by the AIMAR (Interdisciplinary Association for Research in Lung Disease) Task Force
for early diagnosis of chronic respiratory disease based on the WHO/GARD model and on available evidence and
expertise –after a general examination of the main epidemiologic aspects, proposes to integrate the above-mentioned
existing documents. In particular: a) it formally indicates on the basis of the available evidence the modalities and the
instruments necessary for carrying out secondary prevention at the primary care level (a pro-active,‘case-finding’approach;
(Continued on next page)* Correspondence: snardini@qubisoft.it
1Pulmonary and TB Unit, Vittorio Veneto General Hospital, Vittorio Veneto TV,
Italy
Full list of author information is available at the end of the article
© 2014 Nardini et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Nardini et al. Multidisciplinary Respiratory Medicine 2014, 9:46 Page 2 of 31
http://www.mrmjournal.com/content/9/1/46(Continued from previous page)
assessment of the individual’s level of risk of COPD; use of short questionnaires for an initial screening based on
symptoms; use of simple spirometry for the second level of screening); b) it identifies possible ways of including
these activities within primary care practice; c) it places early diagnosis within the “systemic”, consequential management
of chronic respiratory diseases, which will be briefly described with the aid of schemes taken from the Italian and
international reference documents.
Keywords: COPD, Early diagnosis, Guidelines, Prevention, Respiratory diseasesReview
Defining the responsibilities
The United Nations in 2011 identified chronic non-
communicable diseases as the health priority of this decade
[1]. Also the World Health Organization (WHO) defines
chronic diseases as a global threat and includes among the
major diseases - besides cancer, cardiovascular diseases and
diabetes - also chronic respiratory diseases, chiefly COPD
[2]. According to the WHO documents [3] the epidemic of
chronic diseases can be combatted only through prevention
(primary and secondary) and an integrated treatment of the
disease after the diagnosis.
The means proposed include firstly the development of
national programs of prevention and control of chronic
respiratory diseases, aimed not only at defining the most
pertinent healthcare strategies and actions, but also at
raising political and social interest about this issue of pub-
lic health. Alongside these initiatives also fundamental are
the awareness and health education of the general public
(for primary and secondary prevention) and training of
healthcare professionals (not only in responding to citi-
zens’ needs regarding primary and secondary prevention,
but also for appropriate treatment to the patients, a treat-
ment that must integrate the various points of view of the
stakeholders).
Adherence to treatment and integrated care are consi-
dered the best means to reduce inappropriate treatment
practice, which represents not only a cost for society but
also a risk for the individual. One of the most striking ex-
amples of such costs are admissions to Emergency Care,
which, in the United Kingdom, show COPD as ranking 1st
among the chronic diseases and asthma 3rd as a cause for
recourse to Emergency Care [4].
To attain these goals - fundamental for an optimal
care of all chronic diseases - the organizational require-
ments are as follows: a) a greater role played by general
practitioners (GPs); b) creation of intermediate levels of
care between primary care and the hospital (involving
better and faster communication between the specialist
and GP - these last organized possibly in some form of
association - as well as a more rational use of telemedi-
cine); and c) structuring of home and community care,
which includes also redefining the role of the hospital
for acute patients and the creation of intermediateinpatient facilities between the hospital and the patient’s
home [5].
Specifically concerning COPD - and in general valid for
almost all chronic respiratory diseases - the actions to be
implemented have been identified in a document of the
United Kingdom published a few years ago that estab-
lished the priorities for the National Health Service as
follows: 1. prevent the development of COPD through a
significant reduction of the number of smokers in the
community; 2. improve diagnosis of COPD, in particular
through a more widespread use of spirometry tests; 3. help
patients to self-manage their own disease through respira-
tory rehabilitation; 4. integrate the care of patients affected
by COPD, i.e. link specialist care to primary care [6].
In accordance with the above, in COPD - as for
chronic respiratory diseases generally - the State and
National Health Service are responsible for planning (and
funding) the most appropriate actions for the various
levels of preventive action (some of which are common to
all other chronic diseases) and for integrating the health-
care services. It is the responsibility of health professionals
(and their Scientific Societies) to know about and apply
the fundamentals of prevention and treatment including
their relative organizational aspects. General Population
have the responsibility to learn about the behaviors that
promote health ("health education"), as well as the charac-
teristics of the early phases of respiratory diseases (so they
can confirm or disconfirm their existence through the
appropriate actions of secondary prevention). Patients
Associations should help associates (both patients and
relatives or caregivers) in the educational process for self-
management of disease once it is manifest ("education
about the disease") as well as advocate for public and pol-
itical awareness of the burden of the disease.
The size of the problem and consequent strategies
In Italy, as there is no register for such diseases nor a
corresponding exemption ticket, precise and reliable of-
ficial data concerning COPD are lacking. Moreover, and
not only in Italy, a large underestimation of the disease
itself has been demonstrated.
In Italy in 2001 - based on WHO data - out of a total
556,892 deaths 64,984 were due to respiratory causes: of
these, 31,968 deaths were due to lung cancer, 16,295 to
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monia and 8,344 to other respiratory causes. In 2006,
there were in Italy (excluding deaths due to lung cancer)
35,751 deaths due to respiratory causes (57% males)
representing 6.4% of all deaths. In 2008, 37,659 deaths
were registered (6.5% of the total mortality). Of these,
the deaths due to asthma were 474, while those due to
COPD, chronic bronchitis, emphysema and other chronic
obstructive diseases were 20,786 [7]. Respiratory diseases
all together thus represent the 3rd ranking cause of mor-
tality (or 2nd, if lung cancer is included).
These are deaths that mostly affect the more advanced
age-groups, and approximately half of them are due to
COPD; nevertheless, when the moment of death arrives
the patient will have already lived many years of invalidity
as shown by the European Community Respiratory Health
Survey (ECRHS) which highlighted that in the 20-44 years
age-group new cases of COPD per 1,000 inhabitants each
year range from a little more than 1 to almost 3 depending
on the criterion of obstruction utilized [8].
On the basis of the National Institute of Statistics
(ISTAT) data, about 5% of adult Italian males are allegedly
affected by COPD and about 4% of women, but as noted
clearly in the COPD guidelines of AGE.NA.S: “This esti-
mate, that places COPD in 6th position of chronic diseases
present in Italy and which, translated into an absolute
value, identifies more than 2,600,000 Italian citizens as
affected is almost certainly an underestimate of the real
dimensions of the prevalence of the disease” [9].
This statement is confirmed by a recent Italian study
that compared the data of prevalence drawn from admin-
istrative records with the general medicine database
(Health Search) and with estimates based on ISTAT data.
This study, while it showed good agreement between the
three sources concerning diabetes, heart failure and ische-
mic heart disease, revealed COPD prevalence based on
administrative data to be markedly lower with respect to
the data from general medicine [10].
More in line with the picture that emerges from the
international literature are the data of Viegi et al., on the
basis of which 9.9% of people between 25 and 45 years
suffer from obstructive disorders while in the overall
age-range of 25-73 years 11%, 18% and 40% of people
are affected depending on whether one applies, respect-
ively, the criteria of the European Respiratory Society
(ERS), clinical criteria, or those of the American Thoracic
Society (ATS) [11].
Slightly lower prevalences have been reported in the
past by the Italian GPs (SIMG) network (Health Search),
which shows 4.5% of the general population as affected
by COPD, and well over 8% of males and 4% of females
aged over 65 years [12].
Concerning the different levels of disease severity and
according to the previous GOLD staging, Viegi’s groupshowed the COPD prevalence in Italy as follows: for
males, 14.2% = stage 0 or at risk (people with chronic
cough or sputum production), 12.3% = stage I or mild,
4.5% = stage II or moderate, 0.4% = stage III-IV or severe-
very severe; for females, 10.1% = stage 0 or at risk (with
chronic cough or sputum production), 7.3% = stage I or
mild, 2.2% = stage II or moderate, 0.3% = stage III-IV or
severe-very severe. Similar results have been found also in
other countries [13].
These are figures that evidence an epidemic trend,
which needs to be faced as a real emergency. An emer-
gency all the greater considering that - as said before -
this frequency is high notwithstanding the figures are
underestimated [14]. Underestimation derives mostly
from the fact that a disease with a low profile or visibil-
ity is also less often suspected (compared to other more
“publicized” diseases) and consequently less often investi-
gated diagnostically. A classic example are patients who
report dyspnea on exercise: they are almost always re-
ferred for an electrocardiogram or to a cardiac specialist
and consultation by a pulmonologist comes only at a
second or even third step. Patients with COPD (but also
asthma) are often undertreated to the point that not even
those affected know they have a chronic obstructive dis-
ease [15]. When one compares patients’ awareness about
their disease with that of other chronic pathologies, such
as diabetes or hypertension, one sees that only a fifth
(20.6%) of patients with COPD are aware about their
disease compared to 94.3% of diabetic patients, 69% of
patients with hypertension and 57.2% of heart disease pa-
tients [16]. Of note, in the same study, only slightly more
than 17% of patients affected by COPD remembered hav-
ing received advice to quit smoking.
Underdiagnosis has mostly been investigated by
studies abroad that report percentages of missed
COPD diagnosis ranging between 75% and 91% in
Sweden [13] and 80% in the United Kingdom [17,18].
Strange as it may seem, even severe cases, despite the
fact they provoke significant respiratory symptoms, are
diagnosed in only half of the patients. The studies just
mentioned found in fact that missed diagnosis of
COPD regarded 50% of severe cases, 81% of moderate
cases and more than 99% of mild cases in Sweden,
while in the United Kingdom only 46.8% of cases of se-
vere or very severe COPD had received a diagnosis of
respiratory disease.
In Italy, a recent qualitative study that used the ap-
proach recommended by GARD/WHO, i.e. social com-
munication - with posters and leaflets placed in the GP’s
office and television ads - and offering a free spirometry to
all who considered they had symptoms of respiratory
disease, found chronic lung disease to be present in 356
(86%) out of 414 people who presented spontaneously, of
whom 320 (77% of the total and 90% of those affected)
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221 people found with COPD) were already known to
have COPD [19].
Besides the above-mentioned studies, others have
reported, in large-size samples with “functional” confirm-
ation of the clinical suspicion, a prevalence of bronchial
obstruction in adults in industrialized countries of up to
16% [20], but which a recent review has shown can reach
as much as 37% depending on the group examined and
the criterion used for diagnosis of COPD and of bronchial
obstruction [21]. The previously cited study [18] carried
out on more than 8,000 British adults over 35 years of age
showed a prevalence of COPD (defined with spirometry)
of 13.3%. Overall, the most reliable estimates for the global
burden of COPD range from 3.6% to 10.1% [21], from 4%
to 10% [22], and from 9% to 10% [23]. While acknowled-
ging that COPD prevalence can vary in terms of the mean
age of the population, the prevalence of smokers and the
spirometry criteria used, it can be concluded that the preva-
lence of COPD in developed countries - and hence also in
ours - can be estimated at probably 10% or more in indi-
viduals over 45 years of age, with a cumulative incidence of
5% of new cases (according to GOLD criteria) over a period
of seven years in individuals aged 45-79 years, previously
healthy from the respiratory point of view [24].
If the first cause for missed diagnosis of this respira-
tory disease is low patient sensitivity about the symp-
toms themselves of the disease, when symptoms finally
are reported to the doctor scant use is made by the latter
of the procedures that could correctly lead to diagnosis.
In a study carried out a few years ago, only about half of
patients who reported symptoms performed a spirometry
test [22]. The situation is worse still in Italy: based on the
aforementioned Health Search data, only about 30% of the
cases of (recorded) COPD diagnosis are accompanied by a
spirometry test [25]. Also in the hospital setting the per-
centage of COPD diagnosis with spirometry documen-
tation is decidedly lower than expectations, with mean
values around 15% in internal medicine departments [26]
and around 60% in the pulmonary setting [27].
Besides being harmful for the individual affected, this
underestimate and under-awareness involves a cost for
society (for late diagnosis and inappropriate treatment
which in turn lead to a not-inevitable number of cases of
invalidity) and a drain on healthcare resources (for inad-
equate or nonexistent planning of specific patient care -
in Italy there is still no exemption for medical costs
related to COPD). In fact the costs of non-programmed
care - a consequence of underdiagnosis - can double those
of programmed care [28].
Last, it is worthwhile noting that COPD care already
now represents a high cost for the community: it is the
7th ranking cause for number of admissions and for cost
of hospital stay, and the 2nd for mean length of stay, witha percentage of hospital admissions that represents 1.2%
of the total. Hospitalizations for COPD constitute more
than 6.5% of the total; based on U.K. data [29] respiratory
diseases constitute the leading cause for visits to the GP,
coming before even those for musculoskeletal problems.
Also based on the same source, respiratory diseases repre-
sent the 2nd cause for access to the Emergency Ward, after
accidental lesions (wounds, injuries and poisoning) [29]. A
patient treated at home with long-term O2 therapy costs
approximately 4,500 euro per year [30].
The general prevalence of chronic respiratory diseases
and hence the cost of their care are destined to rise,
given that such diseases and the relative consequences
are events associated with the elderly and, moreover,
that advances in healthcare are improving patients’ mean
survival.
In conclusion, using with prudence the above-mentioned
estimates (i.e. from 4 to 10% of the population) about 3
millions people would be affected by this disease, i.e. more
or less the same number as those affected by diabetes
(4.9% of the general population: 5.0% of females, 4.7% of
males), i.e. almost 3 million people [31] - a chronic disease
that benefits from very different medical and social funding
and a very different attention on the part of health profes-
sionals. It is not by chance that WHO recommends the
adoption of initiatives to raise awareness about the epi-
demiological importance of COPD through advocacy both
of the wider public and of politicians and decision-makers
in general [3].
Global management of COPD
As said, the management of COPD and chronic respira-
tory diseases generally needs to be put in the context of
today’s healthcare in which chronic invalidating diseases
have an overwhelming prevalence (cancer, diabetes and
cardiac disease as well as respiratory diseases). In addition
to the increase in the number of people affected by these
diseases due, as already mentioned, to the growing average
age of the population, the cost of their care is rising due to
the development of new, effective pharmacological treat-
ments and new rehabilitation protocols that increase still
further the life expectancy. These trends place the accent
on the sustainability of the healthcare budget: if today
there is 1 person over 65 years for every 2 people of an em-
ployable age, this ratio is destined to become inverted in
the short term and we will have 2 elderly for every 1 person
of an employable age. For this reason, in the U.K. - which
has a national health system (NHS) similar to our own - a
debate has arisen about reorganizing the health system in
relation to chronic respiratory disease [32]: the NHS should
in future help citizens to choose a healthier lifestyle through
health education and information, promoting a healthy
“air” environment, and offering them integrated services of
primary, secondary and tertiary prevention.
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ensuring care for already existing chronic diseases (with
the aim to reduce their invalidating consequences through
early diagnosis and rehabilitation), implement actions
aimed at preventing the onset of new ones. Part of the
care for currently existing diseases is an optimization of
the existing services (which includes a reduction of the
inappropriate healthcare practices) and their integration.
By way of example, currently care for chronic diseases is
prevalently hospital-based, but it will have to organize
itself differently to become prevalently based in the local
community. Also in Italy we have begun to face this
problem with government document “Gaining health”
(“Guadagnare salute”) produced in the spring of 2007
that highlights the importance of prevention in community
health management (at all levels) and the relative strategies
and consequent working actions to achieve it [33].
In Italy, as in the U.K., the possible remedies at orga-
nizational level are:a greater involvement of GPs and the
creation of intermediate levels between the assessment
carried out in the GP’s office and hospital, with more fre-
quent and faster communication between specialist and
GP (ideally the GP should be located in an office in asso-
ciation with other GPs); a rationally designed use of
telemedicine; and a better structuring of homecare, with a
greater presence and integration of community nurses.
GARD-Italy, under the auspices of our Ministry, high-
lights also the importance of fighting risk factors, of antici-
pating the diagnosis and, thus, of a system of care aimed
at preventing/delaying complications, relapses and pro-
gression of the disease [34].Figure 1 General flow chart for COPD management. From [35] mod.A way to put into practice the general principles outlined
above is exemplified in the flow diagram in Figure 1 modi-
fied from the joint statement of the three leading scientific
societies in Respiratory Medicine in conjunction with a
scientific society of General Medicine, The Integrated
Management of COPD [35]. The cited document and
relative flow diagram were used - together with the Italian
AGE.NA.S guidelines on COPD [36] and with the
documents of GARD/WHO and GARD-Italy (see
below) as a basis for elaborating the model in the present
document.
The flow chart represents the general management of
COPD and can serve for the management of any chronic
respiratory condition (accordingly modifying the instru-
ments for early diagnosis). The general population must
be stimulated and assisted to keep healthy: this is
achieved through health education (which means guid-
ing them to choose healthier behaviors) together with
the elimination of outdoor air pollution (through appro-
priate legislation and continuous monitoring of air qual-
ity), education about indoor pollution control, and
tobacco control.
It is possible to identify in the general population indi-
viduals who, as bearers of fragility or defects or particular
characteristics, have a predisposition to develop disease:
identifying them allows the maximum individual tailoring
of interventions (so-called “predictive” medicine). For ex-
ample, as interventions of predictive medicine one can
intend actions addressed at evaluating cholesterolemia in
the prevention of cardiovascular diseases. Concerning
COPD, the best available tool for identifying persons most
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National Research Center (CNR) and National Institute of
Health [37].
Persons identified through the use of risk cards - in one
of the possible modes (see below) - or those who due to
presence of respiratory symptoms - even generic - are sus-
pected of COPD undergo an early diagnosis procedure
based on spirometry as the method of choice. Once the
diagnosis of COPD is made the patient enters a treatment
process based on self-management, aided by education
about the therapy, programmed integration between hos-
pital and local community, and pulmonary rehabilitation
(PR), the goal of which is to delay the invalidating conse-
quences of the disease. With the progressive worsening of
the disease, home care must be organized and, in the final
phases, pain care and end-of-life care. Through these
organizational modalities, and only in this way, COPD
care (and that of the other chronic diseases) is based on
an appropriate use of resources and is sustainable by the
community, as demonstrated by the U.K. hospitals clinical
audit system [38].
All points presented in the flow chart - in particular
the issue of early diagnosis - will be discussed in the
following paragraphs.
Primary prevention of COPD
Primary prevention signifies prevention of the occur-
rence of chronic respiratory disease. This is achieved
principally, but not only, through a consistent reduction
of the number of smokers in the community, together
with health education and indoor and outdoor pollution
control (Figure 2).
In fact the WHO estimates that only about 42% of the
global epidemiologic burden of COPD is due to environ-
mental exposure: in particular, occupational exposure
would account for 12%, and domestic exposure to home
cooking fuels for 22% (bear in mind that these are esti-
mates regarding the whole world for which there areFigure 2 Interventions for primary prevention of COPD.obviously different living conditions from those character-
istic of the western world, in which this exposure is far less
important). Outdoor pollution is estimated to be respon-
sible for 3% of cardiopulmonary mortality. On the con-
trary, the preponderant role of smoking is underlined by
the same WHO estimates: for COPD active smoking alone
contributes to about 38% of the global burden [39].
Reduction in the number of smokers is brought about,
at the level of the general population, by legislative and
commercial measures (bans, sales limitations, taxation)
rather than through health treatments. These latter, in
particular the most individually tailored ones (and, where
necessary, the most “intensive”) are reserved for those
within the general population who on account of their
characteristics (genetic, habit- or lifestyle-related) are at
greater risk than others. Particular effort hence will be
spent on identifying them (predictive medicine) and direc-
ting them a priori to the appropriate care.
In reducing the number of smokers one acts not only
on the principal cause of COPD but also on the principal
risk factor of other prevalent chronic diseases. Smoking in
fact contributes overall to about 12% of the risk expressed
in disability adjusted life years (DALYs), hypertension
being responsible for approximately 9%, overweight for
8%, alcohol and cholesterol for about 6%, and physical
inactivity for 3%.
In the general population tobacco control is to be
understood as a primary prevention measure, i.e. aimed
at avoiding the onset of diseases linked to smoking itself,
and it should be held quite distinct from the role that
smoking control has in the people already affected by
disease (see section How to organize treatment: smoking
cessation and related pharmaceutical drugs). The control
of this cause of diseases is the most important measure in
the field of prevention of chronic diseases and can be
achieved either by impeding smoking initiation of adoles-
cents not yet smokers or by making already active smokers
quit smoking before they develop a disease. The two ap-
proaches are not alternatives but, rather, complement each
other; nonetheless of the two strategies the one that ob-
tains best results in the short term is smoking cessation of
active smokers. In fact, while the health benefits of non-
initiation will be seen after approximately one generation
(i.e. after about 20 years), within just a few days of smoking
cessation the ex-smoker enjoys health benefits, in particu-
lar cardiovascular benefits, the full effects of which are
revealed over a period of about 16 years. Essential for
the success of both approaches is that they are imple-
mented in a social and cultural context that is able to
control smoking from all points of view - legislative, com-
mercial and price regulation - focused on protecting the
health of non-smokers. The guide for all these actions is
the Framework Convention on Tobacco Control (FCTC)
of the WHO, a convention to which also Italy has adhered
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of the strategy are summed up by the acronym MPOWER
(Table 1) which refers to the document [41]. The offer of
services for smoking cessation (made obligatory by article
14 of the FCTC) permits - as shown above - to act for the
prevention not only of chronic respiratory diseases but
also of chronic diseases other than respiratory which rep-
resent the great majority of the causes of death and inval-
idity in our community.
Both prevention of smoking initiation in young non-
smokers and smoking cessation in adult smokers represent
effective strategies of prevention of COPD (and of other
smoking-related diseases). However, as shown above, pre-
vention of initiation yields results after 20-40 years, which
is the mean time interval between the beginning of expos-
ure to harm from smoking and the onset of a disease cor-
related to it.
As said at the start, it is also important - though less - to
control outdoor and indoor air pollution. This theme is
intertwined with the more general one of health promo-
tion [42] which is not simply healthcare but the result of
coordination between all sectors and subjects whose acti-
vity is fundamental for the health of the community. In
these fields of health promotion the role of the health
services is definitely marginal accounting for about 15%
compared with socio-economic factors and lifestyle
(which account for about 50%), the environment (about
20%) and genetic heredity (15%). For this reason one
speaks of “intersectorial” interventions of health promo-
tion to underline the role, for example, of control of pol-
lution from vehicles brought about through advances in
the design of internal combustion engines or through
the modification of urban and transportation policies.
For what concerns indoor pollution, a distinction should
be made between that of the workplace and that of the liv-
ing environment. In the first case legislation and control
based on sanctions play a leading role, in that they
can regulate the exposure of workers to substances thatTable 1 Strategy for smoking control according to the
Framework Convention on Tobacco Control (FCTC) of the
WHO
Objective 3: To promote interventions to reduce the main
modifiable risk factors e.g. tobacco use
Key areas of actions for tobacco use reduction
● Monitor tobacco use through tobacco prevention policies
● Protect people from tobacco smoke in public places and
workplaces
● Offer help to people who want to stop
● Warn people about dangers of tobacco
● Enforce bans of advertising, promotion and sponsorship
● Raise tobacco taxes and prices
From [41], mod.are potentially dangerous for the respiratory system. Con-
cerning the home and living environment, while in public
spaces legislation and repression still have a role, for the
home environment only health education is valid. One
should bear in mind that the chief role in domestic pollu-
tion in industrialized countries is played not only and not
so much by gaseous products originating from combustion
but by passive smoking to which about half of European
children are allegedly exposed [43].
The combination of preventive measures includes also
education about a healthy lifestyle, which includes eating
and physical activity. In this context - more specifically a
matter of the health sector - interdisciplinary collaboration
and integration assume a great role: respiratory disease
specialists interact with the Department of Prevention, re-
gional health and social welfare services, and GPs.
Secondary prevention of COPD (early diagnosis)
The rationale of early diagnosis
Given the epidemiologic values outlined above, of absolute
importance, the National Health Service cannot act only
passively (passive diagnosis) but must become a promoter
of a series of actions in the field of primary and secondary
prevention, and of rehabilitation.
The “2011-2013 scheme of the National Health Plan”
[44] states that the management approach to chronic re-
spiratory diseases that is capable of providing an optimal
healthcare at a sustainable public costs includes “primary
prevention and earliest possible diagnosis with standard-
ized instruments, followed by rapid and appropriate
treatments so as to prevent or delay invalidity, treating the
chronic patients as much as possible in the community”.
The document intends thus early diagnosis and not simply
the promotion of interventions of information and educa-
tion in the fight against the main causal agents (chief
amongst which is smoking), or the activation of programs
of reduction of occupational and environmental risk (about
which we spoke earlier).
As already outlined, COPD is currently diagnosed at a
late or even very advanced phase; in Spain it has been
documented that only 60% of those who have chronic
respiratory symptoms report to a doctor and only 45%
of these are then referred for a spirometry [45]. The
consequences of this situation are that, at diagnosis, the
person’s physical performance is already largely compro-
mised and the therapeutic interventions are less effective
(see next paragraph). For this reason the National Health
Plan stresses the need to arrive earlier at defining the
presence (or absence) of the disease.
Early diagnosis (which should always be understood as
a clinical, not just functional, diagnosis: see Figure 3) is
considered important because it enables one to act im-
mediately on the causes of disease (first of all, cigarette
smoking) so as to impede or delay the effects of the
Figure 3 Interventions for early diagnosis of COPD. From [35] mod.
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and invalidating symptom levels [46,47].
It is known that only smoking cessation (apart from oxy-
gen therapy in the advanced phases) can alter the natural
course of COPD and improve survival in those affected
[48]. In addition, by administering the most appropriate
pharmacological treatments and - above all - commencing
pulmonary rehabilitation in the initial phases of the dis-
ease it is possible to reduce exacerbations and improve
the quality of life [46]. Initiating in this phase also in-
terventions of education about the disease enables one
to lighten the burden of stigma and depression that follow
diagnosis. Since these psychological factors influence pa-
tients’ adherence to treatment as well as their quality of
life the physician should know about them and know how
to diagnose them [49].
If, then, secondary prevention offers these benefits, the
next question to ask is who should undergo COPD
screening: the general population? symptomatic individ-
uals? subgroups at risk?
Population targets for screening
There is consensus that diagnosis should be based on
screening of people at risk rather than screening the whole
population. The latter would be hardly cost-effective given
that the prevalence of COPD seems relatively modest inthe general population whereas it is markedly elevated in
smokers over 40 years of age [3]. Moreover, the system in
Italy of hospital divisions of Pulmonology and Respiratory
Pathophysiology as the locus for performing and analyzing
the spirometry tests would in any case be insufficient to
handle the great number of respiratory pathophysiology ex-
aminations needed to “screen” the entire population. Con-
sidering the global situation world-wide, also GARD/WHO
does not recommend planning of spirometry tests for each
single individual at risk [3].
It thus appears more suitable to diagnose unknown cases
based on the recognition of symptoms that become mani-
fest (i.e. a greater diagnostic suspicion) and/or through an
evaluation of the level of risk that a person might have de-
veloped COPD when they present to the GP’s clinic for
whatever motive (case-finding medicine) or, also, through
public health initiatives. All these strategies, however, re-
quire greater awareness and sensitivity on the part of GPs
and of primary care in general towards respiratory diseases,
without forgetting that, according to the aforementioned
study [45] a spirometry test was more often prescribed -
and the difference was statistically significant (67.6 vs.
28.6%; p <0.001) - by a pulmonologist than by a GP.
Translated into practice this means that all symptom-
atic individuals aged over 40 years should undergo spir-
ometry. The presence or not of respiratory symptoms
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family history and lifestyle characteristics (risk profile) of
the patient. It should be borne in mind that not always
do patients consider their respiratory symptoms worth
noting and of significance enough to report to the doc-
tor [50,51] - hence the importance of a “case-finding”
approach and of public health initiatives.
Also self-completed questionnaires have been used for
screening in the process indicated by GARD/WHO, for
which they form the first “step” (Figure 4).
As shown above, the presence of respiratory symptoms
often goes unnoticed or is not appreciated by patients who
interpret their own symptoms as due to “physiological”
aging or to their smoking habit. Consequently, they do not
consult the doctor except in the case of episodes of wors-
ening of the symptoms per se due to an exacerbation. More
or less often, in such cases, also the GP underestimates the
situation, diagnosing the episode simply as an acute ex-
pression and not as an epiphenomenon of an unrecognized
chronic condition, omitting to examine in more depth the
clinical picture. The net result, as we earlier pointed out, is
that up to 80% of people with obstruction at spirometry ac-
cording to GOLD criteria were without any diagnosis and,
furthermore, less than half of those with severe obstruction
had been earlier diagnosed [18].
The use of questionnaires with specifically targeted ques-
tions can help throw light on this shadow area, making pa-
tients aware of the need to investigate more deeply their
own condition. In this sense, also initiatives of awareness
raising addressed at the general population and/or at spe-
cific sub populations can help (see below). There is generalFigure 4 A proposal for screening persons with COPD. From [3].agreement that questionnaires are useful and also about
the questions that should be contained in them: age, smok-
ing habit and the duration of smoking (expressed in pack/
years, i.e. number of cigarettes smoked daily multiplied by
the years one has smoked and divided by 20), presence of
cough, respiratory sounds, previous diagnosis of asthma or
COPD, and possibly additional questions related to body
mass index and to the use of respiratory drugs in the past
two years [52-54]. Also the collection of administrative in-
formation about the use of healthcare services in the past
through a specific algorithm can be a useful screening tool
for COPD, endowed with sufficient positive predictive
value to be able to identify individuals at risk of having an
undiagnosed COPD [55]. Instead of the need to have struc-
tured questions put by the doctor or professional nurse or
by the healthcare operator during the patient interview,
questionnaires are preferable in that they can be self-
completed, also at a distance, and eventually completed/
integrated in a subsequent check by the nurse or technician.
There are numerous possible questionnaires that can be
used, followed, in the screened patients, by a simple spir-
ometry test. Some authors propose, as an alternative to
spirometry, to measure the PEF on the basis of some sci-
entific evidence [52,53,56,57]: this measure, however, is
controversial as a diagnostic tool. Some authors [58] have
in fact shown that variations of 1% in forced expiratory
volume in 1 sec (FEV1) are associated to variations (both
in the normal population and in patients affected by bron-
chial obstruction) of 29% in PEF. This is due to the fact
that among the determinants of PEF (elastic recoil, bron-
chial resistance and muscle strength) the contribution of
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muscles) is all the more preponderant the less compro-
mised the other two factors are. All this weakens the use
of PEF, above all in the earlier phases of disease in which
the obstruction is probably not yet very marked.
In the following pages we report the Italian versions,
modified with respect to the original, of two questionnaires
that are easy to use, validated and used in epidemiological
research on COPD. The first is the Respiratory Health
Screening Questionnaire (RHSQ) (Table 2) for the screen-
ing of subjects at risk of COPD [53,56]. To calculate the
risk of COPD, the score is interpreted as follows: < 16.5
points = low risk, 16.5 - 19.5 points =medium risk, > 19.5
points = high risk. The second questionnaire, much simpler
than the first, is the COPD Screener™ (Table 3) which can
be made available also online through internet [59], and it
too has been validated [60].
As an alternative, one can proceed sequentially starting
from the identification of people at risk (these by unani-
mous consent are people over 40 or 50 years of age who
are smokers, or ex-smokers since less than 10 years, or ex-
posed to air pollution) administering as an initial step a
questionnaire that helps to seek the respiratory symptoms
and then submitting only those who result “positive” on
the questionnaire to a simple spirometry test [3,61]. A fur-
ther method is recruiting by invitation to specific people
with certain characteristics to participate in the spirometry
screening - the candidates for screening are thus self-
selected [62]. This latter method, addressing smokers aged
between 40 and 55 years, seems to improve the efficiency
of the screening procedure, given that the frequency of dis-
ease carriers is particularly high.
The possibility of conducting a public health initiative
with an “active call” to individuals at risk of COPD,
along the same lines as already conducted in Italy for
cardiovascular disease, will be illustrated in the next
paragraph.
Summing up, the best approach is one of the se-
quences illustrated in the flow chart (Figure 5), in which
two health professionals characteristic of the Italian situ-
ation are involved, i.e. the occupational health doctor
and the sports doctor, whose role, parallel to that of the
GP (Table 4), can be extremely precious in this phase of
the diagnostic process of COPD.
Role of the GP The use by the GP of the above-mentioned
risk cards [63], available online [64], and/or of the question-
naire would be easy to apply. Inserting them within the on-
line healthcare files in use would make it extremely easy to
identify subjects at risk. Such activity (Table 5) could be car-
ried out by the nursing staff present in group practices,
community primary care units, healthcare homes, health-
care co-operatives, and all those forms of collaborative as-
sociation that offer the possibility of using such personnel.Role of the Sports/Occupational health doctor An
analogous path to that of the GP outlined in point 1b is
suggested also for the other two health professionals in-
volved, who have amongst their tasks to evaluate people’s
respiratory function: the Occupational health physician
and the Sports doctor (Table 6).
Even if, in all these cases, the GP is the key figure [65]
who can successfully accomplish these actions, the GP
must be assured a full coordination between the different
players involved (patients, health workers, and health ser-
vice structures) through the creation of a network that en-
sures “continuing” management of the patient (and not of
the disease or of its single phases) and is centered on the
patient.
In fact the models that attempt to re-design the care for
chronic diseases identify for GPs a series of fundamental
changes: from improving the possibility of access to the
GP’s office to making available a clinical computerized sup-
port, to the possibility of obtaining instant help in clinical
decision making (according to the “point of care” logic) -
also with telemedicine, to support for the patient’s self-
management. Nonetheless, alongside the GP, and often
preceding the GP’s own action, there can be “moments of
contact” with the national health service by the patient af-
fected by COPD but not yet diagnosed, that should be cap-
italized on. We are referring here, besides the contact with
Occupational health physicians and Sport doctors already
mentioned, to use of Emergency services for acute respira-
tory problems. If certain specific characteristics are present,
the emergency care doctor can - when the acute event is
resolved and the person is discharged home - address the
patient in case of suspicion to a follow - up pulmonary spe-
cialist evaluation.
Role of public health initiatives: active prevention
Among the array of possible initiatives, besides the indi-
vidual intervention of the GP and Occupational health
doctor, other healthcare professionals can collaborate
with these two professional figures, integrating their ac-
tivities. In public health initiatives, the effective instru-
ment of prevention, once the target population to
address has been identified, is that of the active call. Ac-
tive prevention represents an articulated group of inter-
ventions, “actively” offered to the population at risk of
COPD. The various subjects of the National Health Ser-
vice involved in activities of primary and secondary pre-
vention are involved in it in an integrated and coordinated
way. Besides these, active prevention presupposes the con-
scious adhesion on the part of the citizen, whose will to
participate in the screening programs and successive
initiatives of prevention is requested. The active call has
the advantage of soliciting interested subjects so as to
implement the necessary actions and optimize the inter-
ventions of diagnosis and care.
Table 2 Respiratory Health Screening Questionnaire (RHSQ), modified
Question Answer Score
1. Age 40 -49 0
Age-group (years) 50-59 4
60–69 60-69 8
2. (a) Are you an active smoker? No O Yes O
(b) How many cigarettes do you smoke per day? Cigarettes
(c) For how many years have you been smoking? Years
3. Using the answers to question 2, calculate your pack/years
N.B. To calculate the pack years you have to do the following operation:





4. What is your weight? kg
5. What is your height? m
6. Using the answers to questions 4 and 5, calculate your body mass index:
N.B. To calculate the body mass index you have to do the following operation:
Weight expressed in kg divided by height expressed in metres squared




6. If you have respiratory symptoms (cough, breathlessness) does the weather influence your symptoms?
Yes 3
No 0
I never have symptoms 0
7. Do you sometimes have a lot of phlegm even if you don’t have a cold or ‘flu?
Yes 3
No 0
8. Do you ever cough up phlegm in the morning?
Yes 0
No 4
9. Do you ever hear “whistling” sounds or other noises inside your chest when breathing?
Never 0
Sometimes/often 4
10. Have you ever suffered from allergies?
Yes 0
No 3
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and are in the course of experimentation - although not
in respiratory medicine - and can have as their objective
both early diagnosis (e.g. the campaigns of screening of
bowel cancer) and true primary prevention itself. A goodmodel for intervention based on the use of risk cards
could be that proposed by a study begun in 2009 in the
Veneto Region regarding cardiovascular disease which is
about to be published [66]. The organizational model
proposed is managed by the Departments of Prevention
Table 3 COPD-population screener™ (mod)
How can you understand if you suffer from pulmonary emphysema?
Mark with a cross the box of the answer that best describes the situation.
The number beside the box serves to calculate the final score.
1. In the last two weeks how many times did you have the sensation of being out of breath?
□ 0 rarely or never □ 1 sometimes □ 2 almost always □ 2 always
2. Does it ever happen when you cough that you feel catarrh or mucus moves?
□ 0 only occasionally when I have a cold or ‘flu’ □ 1 a few days per month
□ 1 most days of the week □ 2 every day of the week
3. What is the answer to the following question that best describers your situation in the last 12 months:
“I do less than I used to because I have breathing problems”
□ 0 I don’t think so □ 1 this happens to me sometimes □ 2 it’s exactly like that
4. Have you smoked more than 100 cigarettes in your whole life?
□ 0 no □ 2 yes
5. How old are you?
□ 0 from 35 to 49 □ 1 from 50 to 59 □ 2 from 60 to 69 □ 2 over 70
Total score: ____________________
If the total is 5 or more your breathing problems could be caused by a disease that is known as pulmonary emphysema or chronic bronchitis and
that doctors call chronic obstructive pulmonary disease (COPD). Talk about it with your doctor, reporting the answers given to this questionnaire.
Remember anyhow that any breathing problem, even banal but which lasts a few weeks or months, could be the signal of a lung disease; to
exclude this it would be a good idea to talk about it with your GP.
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active call) of healthy individuals aged between 45 and
59 years. The Screening Center (SC) of the Department
of Prevention operates in collaboration with the local
health district and GPs: the SC prepares the lists ofFigure 5 Flow chart for COPD diagnosis.residents and submits them to the GPs, who help in the se-
lection of subjects to contact, excluding those among their
patients who bear any of the causes for exclusion (i.e. those
who, on the basis of their records, carry a diagnosis of
neoplasia in the active phase, progressive or severe
Table 6 Process involving the occupational health
physician/sports doctor
● 1. In their activity the occupational health or the sports doctor
performs a simple spirometry test (this is expressly required by law)
or identifies a patient with respiratory symptoms and, based on the
diagnostic suspicion, carries out “on their own” a simple spirometry.
● 2. A spirometry that reveals an alteration requires confirmation
through a comprehensive spirometry or specialist evaluation.
● 3. Simple spirometry that does not show alterations in a symptomatic
patient requires further verifications.
Table 4 Process involving the GP
● 1a. The patient visits the GP because, through a health information
campaign and also by means of a questionnaire, they have become
aware of their own respiratory symptoms.
Or:
● 1b. The patient goes to the GP for reasons other than the presence of
respiratory symptoms, and it is the doctor who seeks for the presence
of respiratory symptoms and traces the patient’s risk profile.
● 2. The doctor confirms or disconfirms the clinical suspicion of COPD.
● 3. In the affirmative, he will get the patient to perform a spirometry test.
● 4. If the spirometry shows an impairment, it requires confirmation
through a global spirometry or a specialist referral.
Nonetheless, people who result negative on the simple spirometry test
but in the opinion of the GP are still suspect of chronic respiratory
disease should be referred for further respiratory function tests, since
simple spirometry is a test of low sensitivity.
Nardini et al. Multidisciplinary Respiratory Medicine 2014, 9:46 Page 13 of 31
http://www.mrmjournal.com/content/9/1/46neurological disease, cognitive decline or psychiatric dis-
ease, and chronic kidney failure). The GP should also ex-
clude any persons who result to the GP already under
treatment for ischemic heart or cerebral disease, arterial
hypertension or diabetes mellitus with therapeutic indica-
tion. Citizens thus identified are invited (“active call”) to
an appointment by letter with an eventual reminder in
the case of non-respondents. Computer management
is provided by a specific software program. To those
who adhere, a healthcare assistant (HA) administers a
standardized questionnaire and records data such as
weight, height, body mass index (BMI), waist circum-
ference, arterial blood pressure, and fasting glycemia.Table 5 Actions for the GP to perform
● 1) Indicate on the clinical record the status of smoker, ex-smoker,
never smoker;
● 2) indicate on the clinical record occupational risk factors
(e.g. welding, zinc workers, etc.);
● 3) train oneself and nursing staff in the use of risk cards,
questionnaires, simple spirometry, and how to perform one;
● 4) use the computerized risk card;
● 5) administer the questionnaire to subjects at risk;
● 6) perform a simple spirometry (see below) for initial identification
of disease;
● 7) perform a global spirometry on subjects with altered spirometry;
● 8) refer patients who present alterations to the pulmonary specialist
for diagnostic confirmation, staging, and therapy prescription;
● 9) monitor subjects at risk who are still without manifest disease,
and try to enroll them in a smoking cessation project;
● 10) refer to the pulmonary specialist subjects with negative results on
spirometry but persistent diagnostic suspicion of chronic respiratory
disease.
The GP should be assisted by:
- a secretary (point 1, 2);
- a nurse under the GP’s supervision (point 3, 4, 5, 6, 7).Based on the results of the interview and the individual’s
conditions the HA proceeds to give the motivating reasons
and the proposal for targeted preventive interventions
differentiated according to the person’s classification in
one of 4 categories (i.e. healthy without risk factors,
healthy with risk factors, with abnormal parameters,
subjects with pre-existing criteria of exclusion but not
excluded due to error).
A similar model (which as can be seen can combine
primary and secondary prevention) could, with the ap-
propriate modifications, be proposed also for primary
and secondary prevention of COPD and would thus give
the community two possibilities of screening: the case-
finding approach on the part of the GP, and “active call”.
On these premises the following flow chart has been
created (Figure 6).
Screening procedures with respiratory function measures
The above model presupposes an increased availability
of spirometry tests with respect to the present and to
achieve this there are diverse options:
1. Spirometry performed at the GP’s office, directly by
the doctor or the nurse, gathering periodically all
the selected patients on dedicated and programmed
(or programmable) days (and hours).
2. Spirometry performed at the GP’s office, by
technical personnel made available by the
department of Pulmonology or Respiratory
Pathophysiology at periodic intervals.
3. Spirometry performed at a Pharmacy by specially
trained personnel [67].
4. Spirometry performed at a facility of the local social
health services - which is usually “closer” and more
accessible to the population than the hospital.
In such cases and always with planning of the
appointments, outpatient specialists or trained
nursing staff linked to the outpatient clinic (when
available) can be requested to perform the
spirometry test. If not available, the feasibility of
carrying out the test by technical staff made
available by the Pulmonology or Respiratory
Pathophysiology Unit can be evaluated.
Figure 6 Proposed model of respiratory disease prevention by active prevention. From [66] mod. Department of Prevention; District; GP;
(*) for clinical assessment and spirometry.
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the diagnosis made or a comment given by the reference
specialist, possibly (where available) through telemedi-
cine. The professional figure who carries out the test
and who assesses the result, in contrast to other proce-
dures, is of great importance, given that the test, to be
significant, must be carried out and recorded “in the
correct way”. In other words, whoever performs and, in
any case, records the result of the test must have ad-
equate training and experience, given that the diagnostic
significance of spirometry is both patient- and operator-
dependent, with full collaboration required between the
two figures involved [68]. Regular calibration of the spir-
ometer is essential and should be done on a regular basis
according to the manufacturer’s indications.
The most frequent error in the phase of execution is
that of a forced expiratory phase which is too-short (this
occurs often in severely obstructed patients) and interruptedearly. This error can be detected only if one can visualize
in real time the expiratory curve, which therefore needs to
be visible in the spirometer used for the screening. To
avoid the error of a too brief expiration, an alternative can
be to assess the FEV1/FEV6 ratio, especially for COPD
screening programs in high risk populations [69]. The fact
that the spirometer contains the predicted values enables
one to make an immediate judgment. If the device is able
to print out immediately a report or if it is connectable to
a printer make the service complete and enables the re-
sults of the test to be saved.Available equipment
Different types of portable spirometers exist that can be
used and managed in outpatient clinics not dedicated to
respiratory pathophysiology. The element for measuring
(transducer) can be a turbine or a pneumotachograph.
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the device must not only be able to memorize the data
collected (for purposes of making a report - also at a dis-
tance - and storing data) but also to show in real time
on the display both the numerical values and, above all,
the curves generated by the patient, in order to allow an
assessment of the reliability and reproducibility of the
test. In alternative, the spirometer must possess these
characteristics when interfaced with a computer. Being
able to view in real time the curves enables, as we said,
to detect immediately the size of the effort made by the
patient and other errors in the performance of the test.
The performance of these portable spirometers has
been compared (particularly in the pediatric setting)
with conventional spirometers. Comparing three groups
of children (with clinical asthma, suspected asthma, and
healthy controls) no significant differences were found
between the two categories of spirometer [70]. A more
recent study has verified the accuracy and precision of
these spirometers in the general practice setting [71]:
80% of the devices were turbine spirometers and 16%
pneumotachograph spirometers. In general all devices
showed a mild overestimation (mean 25 mL) both of
FEV1 and forced vital capacity (FVC)
(a), but some of
them showed substantial deviations. Significantly greater
deviations with respect to the turbine spirometers were
observed in the pneumotachograph type concerning
FEV1 and FVC. Finally, the long term reliability of tur-
bine spirometers has been demonstrated by a 3-year
study carried out in Denmark [72].
In general, the values measured by portable spirometers
although repeatable should not be considered as inter-
changeable with those obtained by conventional spirome-
ters [73], so their use is best as a first step in diagnosing
obstruction and to monitor its evolution in time. Natu-
rally, the technical quality of the device does not guarantee
the quality of the execution of the test given that, as we
said, the periodic calibration, and constant adjustment
based on pressure, temperature and humidity, plus experi-
ence in performing the test are all equally influential on
the success of the test and its reliability [68].
The health operator must know how to instruct the pa-
tient both with words and “body language” (spirometry is a
difficult test also for the patient, especially if ill); in particu-
lar the instruction must cover (and continue throughout
the execution of the test) both the initial phase of the
forced maneuver (peak flow) and the “holding” of the ex-
piratory phase for at least 6 seconds, before taking in an-
other deep breath. For this, points of “bio-feedback” can be
useful to let the patient see the curves while they are
breathing [74], also through incentives with images simul-
taneous to the execution of the forced maneuver.
Not by chance the aforementioned Dutch study on GP
offices showed deficiencies in the calibration [71] andanother study, also in the field of general medicine [75],
showed the existence of serious problems concerning
the training of health operators, the frequency of the cal-
ibrations, as well as the effective use of the device (45%
of those who had a spirometer did not use it). Finally, a
problem that should not be overlooked is the risk of
crossed infections associated to the use of turbine or
pneumotachograph spirometers. These can be prevented
by use of disposable filters [76]. Also disposable trans-
ducers have recently been put on the market.
From what has been said above, it appears evident that
carrying out spirometry in the GP setting is a burdensome
task in terms of the human and economic resources and
time involved. Confirmation of this, in Italy, comes from a
large study carried out a few years ago (on symptomatic
patients only) that showed that spirometry is certainly per-
formable in the general medicine setting, but GPs are not
very enthusiastic about it (mainly because of lack of time)
and it is further complicated by non-negligible problems
regarding the maintenance of adequate standards of per-
formance and interpretation [77].
While not denying that an associated GP clinic or a GP
with particular specific interest can offer such a service
(possible especially if the technical personnel comes from
or has been instructed in a specialized hospital depart-
ment), this latter does not appear currently feasible for the
average Italian context, also because of the time required
for performance of the spirometry, a burden difficult to
support for general medicine that is not strongly organized,
considering the population group which theoretically needs
such a test.
This consideration is not limited only to the Italian
situation. Enright, well-known American respiratory patho-
physiologist, in fact showed that it is better not to do spi-
rometries at all in the primary care setting rather than do
them incorrectly [78] and in an editorial accompanying
a study on spirometries performed by local community
nurses he concluded that it is recommendable to pro-
vide GPs with good quality spirometries rather than
spirometers [79].
How to define bronchial obstruction
Spirometry - regardless of the different techniques - mea-
sures the volumes and flows developed by the patient
while he/she breathes into the device. The test consists
generally of two maneuvers, a slow one and a forced one:
in both cases the patient breathes to the maximum cap-
acity (inspiratory and expiratory), but in the first case in a
slow mode and in the second case with as intense an ex-
piratory force as possible. For a correct analysis of the
forced maneuvers it is necessary to have at least 3 repro-
ducible trials, utilizing for the subsequent analysis the one
with the highest sum of FVC and FEV1. The results are
compared with theoretic, or predicted, values gathered
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the normal population of reference. The theoretic values
should be periodically updated, however, in that the rapid
improvement of social, physical and nutritional conditions
can lead to variations of the reference values. It is known,
moreover, that one of the determining factors for the cal-
culation of predicted values is race (besides age, height and
gender), and the mixture of races typical of the present era
is further cause for caution in using predicted values. The
comparison is thus expressed as a percentage of the mea-
sured to theoretic value and the presence of alterations is
defined by measured values below the normal values.
To assess bronchial obstruction a measured value in
the forced expiration (i.e. the maximum expiratory vol-
ume measured at the first second from the start of expir-
ation, FEV1) is correlated to the measure of the vital
capacity (i.e. to the total volume that can be mobilized
by the person (vital capacity, VC(b), or forced vital cap-
acity, FVC). In the presence of obstruction (or in cases
of doubt) the measure must be repeated “after” the ad-
ministration of a bronchodilator (usually salbutamol 400
mcg, in the absence of contraindications): the persist-
ence of an altered value (see below) or its incomplete
normalization defines the obstruction characteristic of
COPD. If even after the bronchodilator doubt should
persist this is an indication for the execution of a global
spirometry, which include the measure of residual vol-
ume (that should also be performed in all with proven
obstruction for a better functional characterization of
the obstruction: see below).
There exist two criteria for defining the presence of bron-
chial obstruction: the so-called fixed ratio and the lower
limit of normality (LLN). In the first case an obstruction is
considered to be present if the ratio FEV1/VC is lower than
70%. In the second case, the presence of obstruction is di-
agnosed if the measured value is lower than the 5th percent-
ile of a healthy population composed of non-smokers, or
below 88% in males and 89% in women.
There is now as much agreement among respiratory
pathophysiologists that the definition based on the fixed
ratio is inaccurate as there is agreement among pulmon-
ary specialists working in the field about continuing to
use it: more than 86% of 29 units of pulmonology in a
recent study [80]. The main argument of the former is
that it can generate underdiagnosis in young people
(aged under 40 years of age in women and under 50 in
men) and overdiagnosis in the elderly [81], in practice
misclassifying obstruction and generating false positives
in the more advanced age classes (given that respiratory
function declines with age, such as to justify in itself a
reduction of the FEV1/FVC index). This diagnostic criter-
ion for obstruction is suggested also by the recommenda-
tions contained in a joint ERS-ATS statement on the
interpretation of spirometry [82].The fixed ratio is instead recommended by the GOLD
[83] and AGE.NA.S [36] guidelines, inasmuch as there
exist arguments also in favor of use of this latter criter-
ion. The first is the AGE.NA.S acknowledgment that “re-
liable estimates of distribution of the values of the FEV1/
FVC ratio in the various age groups do not exist and that
thus a diagnosis based on values below the 5th centile of
distribution of FEV1/FVC in the reference population
would be impracticable”. Secondly, the excess of prevalence
that one observes with the fixed ratio in the elderly is not
the same for all classes of severity of obstruction, there be-
ing in GOLD class II a greater correlation to the clinical
diagnosis with the fixed ratio than with the LLN [84]. In
addition, the disadvantage derived from an excess of preva-
lence described (less specificity) by the fixed ratio may be
counter-balanced by the advantage of its greater sensitivity,
at least in some age-classes. In fact, those who are diag-
nosed as obstructed with the fixed ratio have more hospital
admissions and a higher rate of mortality than those who
are diagnosed with the LLN; in other words, it could be
that the LLN underestimates COPD (which is not solely
bronchial obstruction - see section How to organize treat-
ment: defining the disease severity) [85].
Finally, given that the diagnosis of COPD, particularly
in the elderly, is never only spirometry-based, but rather
on the contrary diagnostic suspicion (presence of cough,
sputum, dyspnea and history of smoking or exposure to
environmental risks) precedes the spirometry, in the
opinion of pulmonologists “working in the field” and
also of our working group the choice can be left to the
specialist which of the two criteria of obstruction to use,
e.g. with which one he has more familiarity, knowing
that the definition of obstruction can still easily be based
on the fixed limit of 70% in the ratio FEV1/FVC, given
that, as evidenced by the AGE.NA.S guidelines, “the po-
tential diagnostic error, due to the choice of the value
0.70 as the sole lower limit of normality of the FEV1/
FVC ratio, will be reduced by the dimension of clinical
probability of disease before the execution of the spir-
ometry test”. This, for so long as the still missing epide-
miologic data are not available.
In practice for the clinician it is thus sufficient to know
that the use of the fixed ratio determines an area of uncer-
tainty due to the potential cases of under- and overdiagno-
sis, respectively, in young people and in the elderly. He
will thus consider alternative, complementary diagnoses
or investigations (or will refer the patient to a specialist
for evaluation) in elderly with a fixed ratio below 70% but
without typical symptoms of COPD and in young people
with typical symptoms but with a ratio above 70% [86].
Finally, besides writing a correct medical report on the
examination, the specialist will need to make an effort to
write the report in a way that is “legible” and compre-
hensible to the GP: the respiratory scientific societies
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an initiative to standardize the medical report.
What to do after early diagnosis
How to organize treatment: defining the disease severity
Once the presence of obstruction has been diagnosed with
simple spirometry, a person with suspected COPD should
be referred to functional respiratory unit for diagnostic
confirmation that includes global spirometry with revers-
ibility testing. Referral should aim at confirming the diag-
nosis of obstruction as well as at staging its severity so that
he/she can be inserted in the most appropriate therapeutic
course (see sections How to organize treatment: defining
the disease severity, How to organize treatment: educating
patients about their disease, How to organize treatment:
smoking cessation and related pharmaceutical drugs, How
to organize treatment: use of respiratory drugs). Once
diagnosis has been confirmed and the level of severity
established, the course of treatment will consist always in
smoking cessation, pulmonary rehabilitation (in practice,
training in exercise tolerance), reduction of exposure to
pollutants, pharmacological therapy correlated to the dis-
ease severity (not simply to the severity of obstruction -
see below), prevention and treatment of exacerbations, this
latter both at home and in hospital. Accompanying these
measures, of not less importance is education about the
disease(c) which makes the patient a conscious and co-
responsible partner of the treatment (Figure 7).Figure 7 Interventions for blocking the progression of the disease.The aim of early diagnosis is to detect patients who are
affected by COPD (without knowing) at the earliest pos-
sible stage, if possible when still at a mild or moderate
functional stage of obstruction. At such stages, in fact, the
cited interventions (smoking cessation, rehabilitation,
pharmacological therapy, etc.) can significantly reduce the
impact of respiratory function decline and exacerbations,
and improve the quality of life. We repeat that early diag-
nosis must be followed by a staging of the severity and by
the therapy that is most appropriate. It is worth repeating
here also that one must stage and treat the patient consid-
ering the severity of the disease and not that of bronchial
obstruction: it has been demonstrated in fact that bron-
chial obstruction is not the only index of severity that cor-
relates with survival [87] and that equivalent levels of
obstruction can correspond to very different levels of in-
validity and prognosis [88]. This is because disease severity
appears to be determined not only by the impairment of
pulmonary function per se but also by other characteristics
such as symptoms, tendency for exacerbations, nutritional
status and presence of comorbidities.
The specialist will thus have not only the task of con-
firming the spirometry diagnosis of obstruction but also
of classifying its degree of severity in reference to the
GOLD, ERS-ATS and AGE.NA.S guidelines, according
to the scheme in Table 7.
The specialist will need to assess in the COPD patient: i)
the level of dyspnea (diverse scales exist for quantifying dys-
pnea, but the one most widely used – also in Italy [80]- is
the Medical Research Council (MRC) scale [87]) (Table 8),
ii) body mass index (BMI), i.e. weight in kilograms divided
by height expressed in meters, squared, and iii) exercise tol-
erance, measured with the 6-minute walking test (6MWT).
The MRC scale, together with BMI, 6MWT (exercise
tolerance), and FEV1 (bronchial obstruction) in a com-
bined index known as the BODE index provides the most
complete photograph of the condition of a person affected
by COPD (Table 9), and can give a more accurate picture
of the patient’s prognosis than FEV1 alone.
Besides these criteria, in addition to spirometry, also
information about the frequency of episodes of exacer-
bation helps to define the severity of the disease [89] as
well as modifying substantially the impact on the health-
care costs. It appears worthwhile to recall that some of
the cited indices - in particular the MRC scale - could
easily be used also by GPs in their clinical practice.Table 7 Staging the bronchial obstruction
Severity FEV1/FVC after bronchodilatation %predicted FEV1
MILD < 70% > = 80%
MODERATE < 70% 50-80%
SEVERE < 70% 30-50%
VERY SEVERE < 70% < 30%
Table 8 MRC dyspnea scale
Level of
dyspnea
Symptoms referred or reported
0 Presents fatigue after strenuous exercise
1 Averts shortness of breath when walking fast or walking
uphill
2 Walks more slowly than someone of similar age due to
dyspnea
3 Stops after a few minutes or 100 meters when walking
4 Obliged to not move from home; dyspnea when getting
dressed or undressed
Table 10 Global evaluation of the patient affected by
COPD
Dimensions to take into account when defining COPD severity and
verifying treatment efficacy
● Respiratory function
● Quality and intensity of symptoms
● Frequency and severity of exacerbations
● Functional status of the patient
● Therapies: need/adherence
● Satisfaction and quality of life
Table 11 Diagnostic suspicion
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ment outcomes that truly count for persons with COPD
[90] one must pass from an assessment of spirometry alone
to an assessment that takes into account all the above di-
mensions (Table 10).
Hence - in practice - one has to pass from the estab-
lished traditional scheme (Table 11 see (A. Current ap-
proach to COPD)) to a new scheme (Table 11 see (B.
Desirable approach to COPD)) which clearly shows, to-
gether with what has been said above, that the key to
obtaining results cannot but be through integration be-
tween the different health services and, hence, a re-
appraisal of the respective roles of the hospital and local
community services.
Treatment is composed of non-pharmacological ther-
apy and pharmacological therapy that are well described
and analyzed in the AGE.NA.S document and in the
joint societies statement on the integrated management
of COPD [35], and will be outlined in more detail in
paragraph 3.3 and relative subparagraphs.
This global treatment can improve pulmonary function
and quality of life and reduce exacerbations, as long as all
the phases of care are managed in a coordinated and inte-
grated mode, and the person affected by the disease know-
ingly collaborates, i.e. is educated about the disease.
The programmed follow up, i.e. visits aside from those re-
quested by patients themselves on account of clinical varia-
tions arising, will have a frequency that differs according to
the severity of the disease. The suggested schedule of these
visits is reported in Table 12, taken from the joint society
document [35].Table 9 The BODE index
Score (from [91]) 0 1 2 3
FEV1 (%pred.) ≥ 65% 50-64% 36-49% ≤ 35%
Distance walked in 6 mins (m) ≥ 350 250-349 150-249 ≤ 149 m
Level of dyspnea (MRC) 0-1 2 3 4
Body mass index (BMI) ≥ 21 ≤ 21How to organize treatment: educating patients about their
disease
As specified earlier, patient education about the disease
plays a key role in the management of chronic diseases,
and has the aim to make patients themselves an ally in the
care and treatment plan, seeking to change their role from
that of a passive object of the health intervention to the
subject on which this latter is focused. It includes diverse
components, aimed at giving the person essential informa-
tion about the characteristics of their disease, increasing
their motivation and understanding in order to modify the
behaviors, transmitting skills, and providing support for
the emotive aspects of symptoms. These interventions all
together are able to increase the individual’s capacity of
self-management and to guide them to make the best use
of the resources available from the national health system.
Each intervention must also be adapted to the cultural
level (literacy) of the person receiving the intervention:
people belonging to different ethnic groups and religions
and/or with different levels of education will benefit
from different educational interventions.
Self-management is not only of benefit for the patient
and patient’s family but seems also effective in reducing
hospitalizations without side effects or adverse events
occurring [91]; but while for other chronic diseases such
as diabetes there has been significant progress in educa-
tion about the disease, especially in Italy, for COPD
there is still a long road ahead [92].A. Current approach to COPD B. Desirable approach to COPD
Diagnostic suspect Diagnostic suspect
↓ ↓
Spirometry Spirometry, Multi-dimensional evaluation
↓ ↓
Pharmacological therapy Integrated treatment and Rehabilitation
↓ ↓
Spirometric follow-up Multi-dimensional follow-up
Table 12 Recommendations for follow up of patients based on their clinical conditions
Activities Follow up of chronic bronchitis (without
obstruction) and of mild (obstruction
+ FEV1 > 80%) asymptomatic COPD
Follow up of COPD with obstruction
+ FEV1 > 80%, exercise dyspnea
and comorbidities
Follow up of COPD with obstruction
+ FEV1 < 60%, exercise dyspnea,
frequent exacerbations and
comorbidities
Follow up of COPD with obstruction
+ FEV1 < 50%, respiratory failure and
comorbidities
Every two years Once a year Once a year Once a year
Smoking cessation, if smoker All and/or anti-smoking center All and/or anti-smoking center All and/or anti-smoking center All and/or anti-smoking center
Clinical assessment (including




GP, specialist GP, specialist GP, specialist GP, specialist
Pulse oximetry GP, specialist GP, specialist GP, specialist GP, specialist
Simple spirometry GP, specialist GP, specialist GP, specialist GP, specialist
Pulmonologist consultation Pulmonary specialist in the case of
diagnostic doubt
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results, besides face to face teaching sessions or “lessons”
conducted by trained personnel, elements of management
planning (similar to those already available - and well
known - for asthma) have been made available both in the
stable phase and in the case of worsening of symptoms, as
well as telephone contacts made periodically by the refer-
ence person responsible for the care and/or on request by
the patient [93]. The availability of “action plans” alone that
are not integrated into the global education about the dis-
ease can improve the capacity to recognize early exacerba-
tions, but does not seem able to modify either the use of
health care resources or the quality of life [94].
Still in the context of disease education, i.e. as part of the
overall “package”, the availability of tele-assistance can also
play a crucial role [35]. By this term is intended the use of
technologies that go beyond the telephone (made available
for bi-directional contacts) and include also telemonitoring
(which today makes possible control at a distance of spir-
ometry, pulse oximetry, walked distance and symptoms),
telecameras and internet. Such exchange of information
finds its chief indication in the variations of clinical stability
(such as are perceived by the patient) and allows the doctor
to take into account the vital parameters of their own pa-
tient before they decide to seek hospitalization or emer-
gency care [95]. Today we know that the use of these
instruments makes it possible not only to reduce the “ur-
gent” recourse to the national healthcare system but also
to improve quality of life [96].
Care of the psycho-social aspects of the disease is an-
other aspect of disease education: lack of breath induces
the patient to a reduction of physical exercise and auton-
omy, with consequent anxiety and depression. There is
not strong evidence that interventions of this type sub-
stantially influence the use of healthcare resources and
quality of life, but nevertheless the studies carried out on
asthma recommend their use [97].
Smoking cessation is able to modify the natural history of
the disease and, together with pharmacological therapy and
pulmonary rehabilitation, help to improve symptoms, exer-
cise tolerance and, as a result, quality of life. However, in
order to gain the benefit of these treatments, the patient’s
adherence to what is prescribed is of obvious importance.
In COPD it has been demonstrated that such adherence is
very low. The reasons underlying this poor adherence are
multiple, and are linked to patients and their motivation, to
the doctors that prescribe the treatment and their capacity
to be on a “wavelength” with the patients, to characteristics
of the treatment itself, in particular for treatment with in-
haler devices. For these latter the challenge is not only to
develop devices that make the administration as practical
as possible (as has been done for insulin therapy) but also
to simplify the treatment plan, given that the more complex
the therapy is, the greater the risk of lack of compliance,also in view of the fact that the patients concerned are often
elderly, affected by chronic comorbidities and receiving dif-
ferent therapies, often prescribed by specialists who are not
aware of the overall treatment panorama [98].
There are diverse approaches to resolve the problem
of a correct and constant use of inhaled drugs: facility of
use of the inhaler device, knowledge about the patient’s
preferences, the cost of the drugs and of their prescrip-
tion (in Italy people affected by COPD are not exempt
from healthcare costs for the disease), steadfast and pa-
tient teaching on inhalation techniques by the personnel,
the possibility of monitoring the person’s effective cap-
acity in using the inhaler - only to cite the most import-
ant, and they need to be applied all together at the same
time [99].
The use of generic drugs and the substitution of the
drugs prescribed by the doctor with others proposed by
the pharmacist can be a source of confusion for the pa-
tient, especially if he/she has been educated to use one
inhaler device while the drug that the pharmacist actu-
ally gives employs another device.
There is no doubt, thus, that attention to the education
of people affected by disease is an integral part of the over-
all management that should be implemented, and that
such implementation should be without any elements that
are not controllable or a source of confusion.
Patient Associations could play an important role in
this process: they can help associates (both patients and
relatives or caregivers) in the educational process not
only by producing booklets or other printed (or online)
material but also organizing groups for self - help. Pa-
tient Associations could also seek to influence politicians
on the problems encountered by patients and caregivers
in the management of the disease.
How to organize treatment: smoking cessation and related
pharmaceutical drugs
It is well established that smoking cessation slows down
the progression of COPD towards more severe levels of
disease and invalidity (this is due also to its effect on the
frequent smoking-related comorbidities) [36,83]. In the
context of COPD smoking cessation is an essential
therapeutic measure and as such it must be understood,
above all by the doctor that has charge of the patient;
putting it in another way, smoking cessation should be
the first provision made at the moment of diagnosis of
COPD in an active smoker [36,100].
A minimal intervention of the doctor, known also as the
method of the 5 “As” (Table 13) [36] to set a person on the
course of smoking cessation should be carried out in all pa-
tients who are smokers, independently of whether they are
affected or not by COPD, and it can be implemented with
success by nursing staff. If disease is present, the doctor
will add to the usual message (i.e. regarding how cessation
Table 13 Method of the 5 As for smoking cessation
● Ask
Ask about smoking status with open-ended questions
● Advise
Inform about short and long term damage caused by cigarette
smoking as well as about the benefits of quitting
● Assess
Evaluate the patient’s motivation and willingness to quit
● Assist
Help the patient in the attempt to quit smoking
● Arrange
Plan checkups and the follow up
Prevent relapse
From [36].
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formation about the strong therapeutic reasons that make
smoking cessation a ‘must’ and using the respiratory func-
tion tests (principally spirometry and blood gases analysis)
as a motivational lever. It has in fact been demonstrated
that combining the use of spirometry with help in the at-
tempt to quit smoking yields higher percentages of abstin-
ence than not using the respiratory function test [101,102].
The desirability and necessity of a more intense inter-
vention than the minimum are justified first of all by the
fact that there exists a direct dose-response correlation be-
tween the intensity of the intervention (minutes of con-
tact) and its efficacy expressed as the percentage of long
term abstinence [103]) and also by the fact that cigarette
smoking is capable of creating a very strong physical and
psychological dependence. A person who continues smo-
king in the presence of symptoms and notwithstanding a
diagnosis of smoking-correlated disease is considered as
showing a high level of dependence. Thus solely the advice
to quit (which is the most widespread approach used in
Italy) may, in the majority of cases, not be sufficient, and
also the minimum intervention, which in any case should
be always implemented, may not be enough in persons
who almost always have previously attempted on their
own to quit but always relapsed. Thus, based on the per-
son’s clinical conditions and smoking characteristics a
specialized smoking cessation intervention should be
implemented that in addition to pharmacological sup-
port (which should always be administered) can provide
psychological-behavioral assistance [35,36,83].
This type of intervention –which obtains the max-
imum percentage of long-term abstinence – can be pro-
vided both directly by the pulmonologist, if adequately
trained and flanked by a psychologist (also part-time),
and by specialized centers [104] that can be contacted
directly by the patient through the toll-free telephonenumber of the National Health Institute (anti-smoking
toll-free number: 800 554088).
It is important to remember that smokers affected by re-
spiratory disease urgently need to quit and consequently it
is the specialist who must assume a proactive and continu-
ative role, i.e. providing continuing assistance to smoker
patients suffering from respiratory disease with regular as-
sessment of their smoking status, use of pharmacological
therapy and provision of behavioral support, including
treatment in the habitual routine management of their re-
spiratory disease. Pharmacological treatment is aimed at
reducing symptoms of abstinence and the satisfaction de-
rived from smoking, psycho-behavioral therapy at modify-
ing those behaviors that constitute, in the patient’s life,
equally potent stimuli to smoke [100].
In practice, the doctor should collect - and report in the
medical record - specific information on the patient’s
smoking history, measuring the pack/years (i.e. the num-
ber of cigarettes smoked daily divided by 20 and multi-
plied by the years of smoking habit). The doctor should
immediately begin treatment to quit, independently of the
patient’s age, and using first-line active drugs unless there
are contraindications: these are the different forms of
nicotine replacement therapy (NRT) which is available in
numerous formulations, varenicline and bupropion (in
slow-release formulation) for oral administration. The best
mode for judging if the therapy is sufficient is the dis-
appearance or containment of the symptoms of abstin-
ence, in particular craving to smoke; in the case of
persistence of craving the drug dose should be increased or
accompanied by a diverse formulation (if NRT) or by an
additional drug. Doctors who consider themselves not suf-
ficiently trained for this type of assistance should refer the
patient to a specialized outpatient clinic (information about
which can be found in the annual register edited and up-
dated yearly by the National Health Institute [104]).
Whatever the health professional who assists the pa-
tient, all persons affected by COPD should be assessed for
smoking at least twice a year, better at each programmed
checkup. The checkup should include a biological marker
of smoking (expired CO, COHb or salivary cotinine). The
prescription of drugs to quit smoking must be directly
linked to the prescription of the respiratory drugs.
Patients who in no way intend to attempt quitting im-
mediately and in sudden fashion can be proposed a “re-
duction to quit” [105,106], i.e. the use of pharmacological
therapy (see above) while they are allowed to continue to
smoke. The intermediate goal is to reduce, with the aid of
therapy, the quantity of cigarettes smoked daily (to at least
50% of the usual amount in 4-6 weeks). The final goal is
to quit completely within 6-9 months. With this mode,
the most studied drug is NRT that, in the forms as needed
(chewing gum, inhalers, tablets) can be used as a real al-
ternative to the cigarette [107]. The treatment (which
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patient’s preference and smoking habit characteristics)
can be interrupted if the goal of 50% reduction of ciga-
rettes smoked (and a parallel reduction of CO) is not
obtained within six weeks. It can be continued if a last-
ing and significant reduction in the number of cigarettes
smoked has been reached, but telling the patient that
at this point the goal has changed to “reduction of
damage”. If the treatment is successful definitive cessa-
tion can be attempted and, in the case of reaching
abstinence, the therapy is continued for at least two or
three months.
Since the development of lung cancer is more frequent
in COPD subjects, the specialist can when advising to “re-
duce in order to quit” refer not only to the COPD therapy
but also to the prevention of lung cancer [108]. Finally,
there is currently no scientific evidence that the so-called
electronic cigarette can be used with the aforementioned
scope, in that these are non-standardized products that
have not been sufficiently tested [109].
How to organize treatment: use of respiratory drugs
There is agreement among the various official documents
of scientific societies or working groups that the degree of
pharmacological therapy should be based on the level of
severity of the patient, who, as explained above, should
never be assessed only as regards the level of obstruction.
Whatever the level of severity, and beginning right from
mild stages there are common therapeutic measures.
Alongside the first and foremost important treatment, i.e.
assistance in smoking cessation (if necessary implemented
in a “intensive” mode by specialized facilities or health pro-
fessionals) but in any case with the use of specifically activeTable 14 Bronchodilators for the treatment of COPD
Class Drug
Long-acting anticholinergics (LAMAs) Tiotropium
Glycopyrronium
Aclidinium
Long-acting beta-2-agonists (LABAs) Formoterol
Salmeterol
Indacaterol





Short-acting beta-2-agonists (SABAs) Salbutamol, terbu
Short-acting anticholinergics(SABAs) Ipratropium and o
Methylxanthines Slow-release oraldrugs, there should also be prescribed promotion of physical
exercise and anti-influenza and anti-pneumococcal vaccinal
protection. Short-acting bronchodilators “as needed” should
also be recommended (see below = SAMAs or SABAs).
In situations of greater severity (including failed control
of symptoms) beginning from the moderate stage long-
acting bronchodilators (LABDs) should be prescribed,
which exist in two families: the beta-2-agonists and the
anti-muscarinics. Doctors can choose the drug that they
consider most appropriate for the type of patient (individu-
alized treatment) from among the two families, whose com-
ponents are now more numerous than in the recent past.
The characteristics of each of them are listed in Table 14,
taken from the joint society document [35]. One should
bear in mind that the most recent drugs are backed up by
fewer studies of efficacy and safety than the more consoli-
dated drugs.
In still more severe cases (defined also by the presence of
exercise dyspnea) two LABDs can be combined and associ-
ated, in the case of frequent exacerbations or asthma comor-
bidity, with an inhaled corticosteroid (ICS); in this subset of
patients recent studies seem to have shown significant re-
sults also using dual bronchodilation with LABA and
LAMA associated [110,111]. In stages of maximum severity
(i.e. severe COPD, based on the above-outlined parameters)
in patients with a history of frequent exacerbations, a
phosphodiesterase-4 inhibitor can be added to the broncho-
dilator therapy. Theophylline warrants a special note: on
account of its bland broncho-dilating action and due to the
significant side effects associated with its use, the main
evidence for its use is in a small percentage of patients, or -
as recent evidence confirms - in patients with refractory
COPD, to restore their sensitivity to steroids [112]. ApartCharacteristics
Length of action 24 hours
Length of action 24 hours
Length of action 12 hours
Length of action 12 hours
Length of action 12 hours
Length of action 24 hours
asone Length of action 12 hours
esonide Length of action 12 hours
icasone Length of action 12 hours
Oral - Length of action 24 hours
ilator drugs
taline, fenoterol Rapid onsetof action. Length of action 4-6 hours
xitropium bromide Rapid onset but slower than SABAs.
Length of action 6-8 hours
theophylline
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ited to use as an additional therapy in patients with more se-
vere disease when the symptoms persist despite a correct
use of other treatments.
In the advanced stages (very severe COPD), in addition
to continuous oxygen therapy at home (alone in the case
of isolated hypoxia, associated to noninvasive ventilation
in the case of coexisting hypercapnia) antibiotics will be
associated in the case of prevalent symptoms of chronic
bronchitis with hypersecretions while in the case of
a prevalent emphysematous component (localized, not
generalized) the endoscopic application of valves will be
evaluated. Figure 8 [113] helps to position the single
treatment components in relation to the patient’s level
of severity (not, as said before, severity of bronchial
obstruction only).
Finally, one cannot fail to mention the role of nutrition in
patients affected by COPD, who encounter problems of
malnutrition in two cases out of three. In these situations
nutritional support can increase weight (as seen in the para-
graph on staging of COPD, underweight is a negativeFigure 8 A proposal for COPD treatment according to different stageprognostic factor in COPD), muscle mass, and fat mass as
well as improve muscle strength [114].
How to organize treatment: physical exercise prescription
and pulmonary rehabilitation
The reduction of physical exercise due to the dyspnea on
exercise that is provoked by COPD, correlates directly with
a significant decline in quality of life. This reduction often
goes unnoticed inasmuch as the decline progresses slowly
and in its turn it causes further exercise deconditioning,
with dyspnea that appears at less and less demanding levels
of physical exercise.
To combat both the sedentary lifestyle and its conse-
quences it is necessary to recondition the organism to
physical exercise through exercise training; the earlier the
resumption of a reasonable level of physical activity the
better the results will be. If in the initial phases of disease
the patient can be left to self-manage the goals and means
with a group treatment, e.g. through the walking groups
organized by the Departments of Prevention of the com-
munity health service [115], in the moderate to severes of severity and different phenotypes. From [113] mod.
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tured program of Pulmonary Rehabilitation (PR) that will
include not only exercise training but also nutritional assist-
ance, psychological assistance, and education about the dis-
ease. But the first steps that have to be taken before starting
exercise training are, as said before, smoking cessation
(when the patient is an active smoker) and the optimization
of bronchodilator therapy (see above). The contents of the
PR program are summarized in Table 15 taken from the
joint society document [35].
Pulmonary rehabilitation is a multidisciplinary therapeutic
intervention guided by the Pulmonologist and it can be ad-
ministered both in an inpatient regime and as an outpatient
service, or again in the patient’s home depending on the
conditions of the patient and the facilities available. It needs
furthermore to be practiced with regularity, given that its
benefits tend to fade in the course of a few months to dis-
appear completely after one year [116,117]. Besides being
beneficial for the quality of life of the patient (it improves
motivation and mood tone, rendering easier patient self-
management = empowerment) PR, it seems, can also reduce
exacerbations and hospitalizations [36,118]. Today in Italy,
in the respiratory rehabilitation setting there exist almost
only highly specialized centers, there being few community
services, and it is necessary to increase the possibility of
home-based rehabilitation. Nevertheless quite recently there
has been a change in the organization of this sector of
healthcare, and sports medicine has been given responsibil-
ity (for its greater competence in terms of physical exercise)
in providing motor support for the primary and tertiary
prevention of chronic degenerative diseases. And there are
experiences of outpatient management of PR through this
channel that have produced positive results [119].
How to organize treatment: use of oxygen therapy and
ventilation therapy
Besides smoking cessation only long term oxygen ther-
apy (LTOT) prescribed to people with COPD at a severe
or very severe stage with partial arterial oxygen pressure
lower than 55 or 60 mm/Hg (see below) has shown
to be able to improve the survival of people affected
by COPD, providing it is practiced daily for at leastTable 15 Pulmonary rehabilitation
Activities
Essential activities Optional activities
Organize pharmacological treatments such as
are required at the current point in time
Respiratory muscle
training
Upper and/or lower limb muscle training Chest physiotherapy
Health education Nutritional support
Education about therapy
Psychological and psycho-social support
From [35].15/18 hours. Besides survival there is a parallel im-
provement also in the quality of life and cognitive
performance.
The need for oxygen therapy must obligatorily be
established not only with pulse oximetry but also with
blood gases analysis which provides information also on
the carbon dioxide (and thus on the indication for even-
tual non-invasive ventilation therapy) and on the acid-
base equilibrium. Noninvasive ventilation (which patients
generally practice at night) should be assessed when the
partial pressure of arterial carbon dioxide is chronically
above 55 mm/Hg and/or rises dangerously if the hypoxia
is corrected or again if there is present a disequilibrium of
the acid-base condition of respiratory origin (pH > 7.35).
This treatment can be reserved, after specialist evaluation,
for those who, besides hypercapnia, present frequent exac-
erbations and have required repeated hospitalizations [35].
As the prescription of non-invasive ventilation pertains
strictly to specialists, we will not explore this issue in fur-
ther depth here, just as we do not discuss here lung trans-
plantation or volume reduction surgery and the endoscopic
application of endobronchial valves, these latter being
methods used, respectively, for the exeresis and desufflation
of emphysematous areas. The criteria for initiating LTOT
are reported in Table 16, taken from [35].
The procedure for continuing or suspending LTOT is
presented in Figure 9. The goal is to maintain O2 satura-
tions always equal to or above 90%.
Oxygen therapy is available in various forms, from oxy-
gen gas cylinders, to refrigerated liquid oxygen containers,
to concentrators. The first finds practically no indication in
pulmonary rehabilitation: its use is almost completely lim-
ited to emergency conditions or as a temporary supplemen-
tation of other sources when these are not available. Liquid
O2 is versatile and allows mobility. Concentrators are indi-
cated for patients confined to bed although, recently, port-
able concentrator devices have appeared. LTOT can be
administered with nasal tube (more practical and less dis-
turbing) or facial mask (mostly for significant flows or in
special situations) or, in the case of tracheostomy, with an
artificial nose [35].
A review of the LTOT prescription (when this occurs
in the course of exacerbation and not due to the under-
lying disease progression) should always be programmed
within a reasonably short time of the prescription itselfTable 16 Criteria for LTOT
● PaO2< 7.3 KPa (55 mmHg, SaO2< 88%) in stable phase and during
optimal therapeutic regime
● PaO2 between 7.3 and 7.8 kPa (55-59 mmHg, SaO2< 89%) in the
presence of pulmonary hypertension, pulmonary heart, declivity edema,
erythrocytosis (hematocrit > 55%), cognitive deficit
● Patients with manifest hypoxemia during exercise or at night
From [35].
Figure 9 Initial prescription and revised prescription of LTOT. EA, Environmental air. (†) if the patient desaturates during exercise, in some
studies, an improvement of exercise tolerance has been shown; without any effect on survival. From [36]. (*) in the presence of pulmonary
hypertension, pulmonary heart, pitting edema, erythrocytosis (hematocrit < 55%), cognitive deficit. From [35].
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superfluous, or can even worsen, making it useless for
the prior-established goal. Both patient and family care-
givers should be informed from the outset about the
need for an eventual adjustment.
If there exist conditions for continuing LTOT, blood gas
analyses should be included in the treatment plan, simi-
larly as is done for smoking: a control is recommended at
least once a year or in the event of any change in the
patient’s clinical status (see section How to organize treat-
ment: defining the disease severity). The frequency of con-
trols varies from region to region according to protocols
and norms issued by the regional health authorities, but in
general they vary from 3 to 6 months [35].
Notes on COPD care as the disease evolves
In time, as the disease progresses the relative respiratory
failure leads to invalidity and, subsequently, to death.
Care modalities thus become necessary that - added to
those outlined in the preceding paragraphs - assure the
maximum possible well-being of the person through re-
spiratory home care and, in advanced cases, end-of-life
care (Figure 10).
On the other hand, chronic respiratory and cardiac dis-
eases are among the most prevalent causes of invalidity,
while dyspnoea is one of the most frequent (and invalidating)
symptoms: hence home care constitutes a necessary
support for the patients and their caregivers. The
resulting burden for the National health service is not
negligible, both in terms of the costs and the workloadinvolved: Italian patients in LTOT still in 2009 were
prudentially estimated to be about 100 per 100,000 in-
habitants and to generate a cost for the NHS of more
than 250 million annually [120].
Homecare
In general the term ‘home care’ refers to a series of health
treatments provided at the patient’s home rather than
within a healthcare facility. There exist different (increa-
sing) levels of home care, ranging from a simple control of
the person’s general conditions and consumer goods sup-
ply (diapers, catheters, etc.) to specialized home care for
ventilator-dependent persons. The latter care, which comes
under the Pulmonary department of the hospital, consists
in clinical controls and specialized functional monitoring
and it constitutes the true respiratory home care.
In the last few years the concept of respiratory home-
care has evolved to include not only the assistance de-
scribed above, destined for patients already diagnosed and
staged as to their severity and clinically stable, but also sit-
uations of instability due to acute events (e.g. exacerbations
of COPD) not so severe as to require hospital admission
(home care in this case supported by tele-assistance)
[121]. Also the “protected” discharge from hospital of
post-acute situations constitutes part of home care (dis-
charge to home). This modality is also promoted by the
Italian Ministry of Health in a system of integrated
care. Discharge should always be agreed to prior with
the GP, in the context of a formal, informed and agreed
decision [122].
Figure 10 Ways to block the disease progression at the end of life.
Table 17 Healthcare professionals involved in the home
management of patients with respiratory failure
● Referral doctor for integrated home care
● “Specialized” professional nurse
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cently been identified, namely “chronically critical” patients
- these are people who have managed to survive what were,
in fact, critical situations (e.g. a long stay in ICU) leaving
them nevertheless subsequently with enduring states of
organ failure and who, after a stay in the ICU or semi-
intensive care followed by hospitalization in progressively
less “intensive” wards, have arrived home with a need for
mechanical ventilation and a very advanced level of invali-
dity. These are people who have before them months and
sometimes years of stationary conditions. This new cat-
egory of patients, rapidly on the rise numerically speaking,
presents very slow progress (or regression) in their clinical
conditions and a need for assistance by highly qualified
personnel, and it represents a home care target that now is
as inevitable as it is peculiar [123]. Here we will limit our-
selves to the first type of respiratory home care described,
i.e. that relative to known and stable patients, underlining
however that, in the not too distant future, also the other
activities described above will have to be included under
the umbrella of ‘homecare’.
The scope of specialized respiratory home care is to
monitor the situation through planned visits to the home,
generally by a professional nurse with specialist training,
or visits requested (generally by telephone) by the patient
himself or by the GP. A check is made of symptoms, clin-
ical status, and pulse oximetry. If considered necessary the
nurse will perform a blood gases analysis. Symptoms and
signs of clinical instability can be investigated by means of
an outpatient visit and medical check. Exacerbations canbe diagnosed early and treated at home or in the hospital
depending on the clinical conditions and the family care-
giver help available.
In Italy chronic respiratory patients are generally enrolled
in the home care program when they become oxygen- or
ventilator-dependent. In other countries, the enrolment in-
cludes also patients who have encountered in the preceding
year frequent (> 2-3/year) exacerbations, independently of
the presence of severe blood gas alterations [124]. But nat-
urally this depends on the resources available.
Those to whom respiratory homecare is destined should
also receive assistance to quit smoking (if current smokers)
and education on the management of the advanced stage
of their disease, including education about oxygen therapy.
It is claimed that this mode of care, as well as improving
the quality of life of patients in an advanced stage of
COPD, also reduces their need for hospitalizations [124].
We referred to the role of the professional nurse in home
care, but other figures too, if available, should be included
in the home management team of these patients, as shown
in Table 17, taken from the joint document and from the
ministerial document of GARD-Italy on continuing care in
COPD [35,122].
These health professionals obviously should always be
flanked by the patient’s GP, who constitutes the second
level of reference and to whom the service of respiratory
home care reports regarding the patient.
Home care today in Italy appears still far from com-
pletely established, it shows marked and significant varia-
tions between the different regions and, where it has been
studied (perhaps as part of larger studies), poorly funded
[80]. Instead, it ought to be implemented rapidly in order
to respond to the needs arising not only from the increased
numbers of those requiring care, but also from the pro-
gressive reduction of hospitals and the relative number of
beds available.
End-of-life care (palliative care)
Palliative care (which in the final phases becomes end-of-
life care) consists in every intervention offered to ensure
the patient the best possible quality of life, and a dignified
death when this appears close or when the person affected
by chronic respiratory disease does not respond any more
to specific treatments. It does not offer to accelerate or
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the psycho-social aspects of the disease, including assist-
ance to family members [125].
Essentially, palliative care consists in the remission of
the symptoms afflicting the patient: dyspnea, abundant
and/or difficult-to-clear sputum, pain, depression, anxiety,
insomnia, various levels of immobility, and constipation.
These symptoms are present also in terminal cancer pa-
tients and are treated in the same mode [125].
Controlling symptoms is not sufficient to guarantee the
patient the best possible quality of life, if by quality of life
one intends the difference between patients’ expectations
and their real condition of health (i.e. Calman’s gap). While
this latter is influenced by the capacity/possibility on the
part of the palliative care team to contain symptoms and
maximize the residual resources, the patient’s desires and
expectations depend on their awareness of the incurability
of their disease; thus communication of the truth or, better,
accompanying the patient to understanding it represents
one of the main tasks of the palliative doctor.
From an organizational point of view, the best response to
the patient’s needs in an advanced phase of disease is pro-
vided through the network, which includes the dedicated,
multidisciplinary palliative care team, (consisting of a pain
care specialist, nurse, psychologist, social assistant, spiritual
assistant, and others) that interacts with other physicians
based in the hospital (pulmonologist) and local commu-
nity, e.g. the GP and the continuing care physician [126].
Thus, for persons who have reached the final stage of
disease, the group of professionals that is responsible for
the care must include a pain care specialist. At this point,
the role of the pulmonologist passes into the background,
shifting from coordinator of activities (the role carried out
in the overall activities of home care) to that of collabor-
ator with the specialist responsible for pain care, who
must not only possess skills in communication and human
relations, but also knowledge about the treatment options
in the advanced phases of the pathological processes, solid
ethical notions and organizational capacities [127].
If, as said, the scope of pain care is to prevent and allevi-
ate suffering, control symptoms and provide support to
patients and their families in order to maintain and im-
prove their quality of life, then - although pain care was
originally conceived and implemented as an aid in ap-
proaching death - it should in fact be applied at all ad-
vanced stages of disease, both terminal and not, and should
be available for patients at all stages of disease, targeted to
their individual needs and requirements, as well as to the
needs of their families, friends, and those who provide care
as part of their job.
Clinicians who take care of patients with chronic or
advanced respiratory disease or with critical diseases
need to possess or acquire a series of basic skills in pain
care. They should consult pain care specialists so as tobe able to manage their patients in an appropriate man-
ner under the supervision of other expert physicians.
Also attention to grieving both before and after the pa-
tient’s death is recognized as an essential component of
palliative care.
In this patient population, the difficulty in planning
pain care resides in the unpredictability of the course of
disease in the final phases, in that rarely are events her-
alded by a clear, unequivocal moment of transition and,
on the other hand, what was up till this moment a very
slow course can suddenly be precipitated by potentially
fatal exacerbations [128].
These characteristics should orient the national health
system toward greater attention to what the affected per-
son effectively desires in terms of assistance and treatment.
The uncertainty of the prognosis as regards survival means
that, with respect to cancer patients, those affected by
chronic respiratory disease will undergo far more fre-
quently invasive interventions (from mechanical ventilation
to cardiopulmonary resuscitation, to nutrition through
naso gastric tube). Further, both persons in advanced can-
cer conditions and those with very severe chronic respira-
tory disease would appear to prefer the quality of their
remaining life rather than simply a prolongation of their
survival [129]. For this reason is has been suggested to an-
ticipate the entry of COPD patients into palliative care, so
they can be informed from the outset about the predicted
course of the disease and state their preferences regarding
assistance [127,130,131]. It hardly needs to be underlined
that also in this setting the GP as always must be an indis-
pensable part of the team [132].
Conclusions
Primary and secondary prevention of COPD is recom-
mended by the WHO through the model proposed by
GARD. Also Italian ministerial documents and national
and international guidelines recommend such a line of ac-
tion. The end-point of the relative interventions is to im-
prove community health and the care provided to patients
with COPD in a way that is sustainable for the financial
resources of the National Health Service.
On the basis of the WHO/GARD model, while Primary
prevention is based on inter-sectorial interventions not
centered on the healthcare system that aim to improve the
living environment, eliminating or reducing the presence
of gas and particles harmful to the air we breathe, Second-
ary prevention (i.e. early diagnosis) - while including ac-
tions and provisions not strictly pertaining to the health
sector such as raising public awareness (advocacy) about
pulmonary diseases and their most frequent symptoms -
is composed instead of a series of actions that pertain spe-
cifically to healthcare.
Early diagnosis (an intervention which is today a prior-
ity in that it immediately reduces the social and
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Primary prevention measures will not be seen until fu-
ture years) could require greater investments in terms of
organization, human and economic resources on the part
of the national health service. Training of the healthcare
personnel involved by scientific societies and the collec-
tion of data by these latter, that can demonstrate the ef-
ficiency and efficacy of the interventions adopted,
would enable a correct planning of the changes that
need to be made to respond to the effective needs and
would facilitate their implementation.
However early diagnosis makes sense only if the system
is able to follow up with an appropriate, standardized and
sustainable treatment, something that requires not only
the interdisciplinary collaboration of healthcare personnel
but also the collaboration of patients (and their associa-
tions) who must know how and be able to self-manage
their disease.
The challenge awaiting us in the future can be over-
come only if all the components mentioned above can
work together in a coordinated and synergic mode.
Waiting for this coordination to come into full effect, we
must not forget that the current priority in Italy is to
collect and elaborate national data related not only to
COPD epidemiology but also to the characteristics of its
care, beginning with data on continuing care and on
oxygen therapy.
Endnotes
aFor the meaning of these terms, see next paragraph
“How to define bronchial obstruction”.
bIt is beyond the scope of this document to discuss the
greater sensitivity of the FEV1/VC ratio with respect to
FEV1/FVC, or the merits for early diagnosis of examin-
ation of the curve pattern, or flow study at low lung vol-
umes, or the measurement of residual volume as indices
of obstruction.
cBy Treatment Education is intended the transmission
of knowledge, training in performing skills and to pro-
mote changes in behavior, a transmission addressed to
people affected by chronic disease, with the scope of im-
proving the efficacy of treatment by means of their active
and responsible participation in the program of care and
assistance [35]. In COPD the most important, though
not the only, provision for treatment education concerns
training in the correct use of inhaler devices (see section
How to organize treatment: educating patients about
their disease).
*Elaborated by the AIMAR Task-Force for the applica-
tion of the WHO/GARD model on early diagnosis of
COPD.
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